Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

BACKGROUND: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease, with a limited number of progressiv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Berghen, Charlien, Joniau, Steven, Rans, Kato, Devos, Gaëtan, Poels, Kenneth, Slabbaert, Koen, Dumez, Herlinde, Albersen, Maarten, Goffin, Karolien, Haustermans, Karin, De Meerleer, Gert
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7245754/
https://ncbi.nlm.nih.gov/pubmed/32448171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06853-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars